Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study

OBJECTIVE: To evaluate the efficacy and safety of subcutaneously administered fasinumab (REGN475), a nerve growth factor-neutralizing antibody, in patients with acute sciatic pain receiving standard of care therapy. METHODS: This was a double-blind, parallel-group, proof-of-concept study. Patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiseo, Paul J, Ren, Haobo, Mellis, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155988/
https://www.ncbi.nlm.nih.gov/pubmed/25210473
http://dx.doi.org/10.2147/JPR.S65974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155988/
https://www.ncbi.nlm.nih.gov/pubmed/25210473
http://dx.doi.org/10.2147/JPR.S65974

Ejemplares similares